Life science equipment supplier Sartorius has completed the acquisition of selected life science businesses from Danaher Corporation. The prepared integration of the acquired businesses into the two divisions of the Group is now to begin immediately, despite the special conditions during the pandemic crisis.
“The acquisition of this portfolio is a further milestone for Sartorius,” said Sartorius CEO Dr. Joachim Kreuzburg. “We have acquired businesses that are an excellent strategic and operational fit for both divisions. We are pleased to welcome some 300 new Sartorius employees. Together we will become even more relevant to our biopharma and life science customers,” he concluded.
If you want to find more details about the acquisition of Danaher by the life science equipment supplier Sartorius and to read the most important business headlines, download for free the Born2Invest mobile app. Our companion app makes it easy for you to keep informed, to intuitively move from story to story, and from section to section, with no limits on how many articles you can view.
The acquisition will allow Sartorius to further extend its development
Sartorius paid a purchase price of $825 million for the acquisition. The transaction was completed on April 30th, 2020, after the necessary antitrust approvals had been received.
The integration of the acquired businesses into the two divisions of the Group has been prepared since the purchase agreement was signed on October 19th, 2019. It can now be started immediately after completion of the deal, despite the special conditions during the pandemic crisis, the company announced.
The acquired businesses, which generated sales revenue of approximately $170 million in 2019, comprise various laboratory and bioprocess technologies that complement the positioning of both Sartorius divisions.
The broadened portfolio is designed to support customers even more comprehensively in the development of biotech drugs and vaccines and in the safe and efficient production of such drugs. The supplier is thus expanding its market positions in the field of bioanalytics and in key areas of biotech drug production.
Growth for both divisions of Sartorius
Fortébio’s label-free analysis of biomolecules business includes innovative devices for protein analysis, biosensors and reagents used in drug discovery and integrated into the bioanalytics business within the Lab Products & Services division. The products are based on patented biolayer interferometry technology and perform real-time analysis of various biomolecular interactions. The company employs around 200 people worldwide with production facilities in Fremont, California, USA, and Shanghai, China, and accounts for slightly less than half of the sales of the acquired portfolio.
With the chromatography systems and gels also acquired, Sartorius is expanding the portfolio of its Bioprocess Solutions Division in the downstream processing area. The business addresses a key step in the purification of biopharmaceuticals and comprises both reusable and disposable technologies, columns and gels.
The downstream processing position is further strengthened by selected product groups in the areas of stainless steel hollow fiber and disposable crossflow filter systems and flow kits. Also assigned to the Bioprocess Solutions division is the Solohill business unit, which comprises a microcarrier technology and particle validation standards for cell culture processes and other bioprocesses. The various units employ a total of around 100 people at their sites in Portsmouth, UK, Cergy, France, Ann Arbor, Michigan, USA, and Hopkinton, Massachusetts, USA.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in Pharma+Food, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Do Buy/Sell Ads Work on Equity Crowdfunding Portals? The Experience of CrowdFundMe
The bulletin board facilitates the liquidity of financial products placed by CrowdFundMe, allowing the meeting between the supply and demand...
Bitcoin’s Price Crash to Below $30,000 – Altcoins Lose More
Just a few days ago, Robert Kiyosaki had announced a Bitcoin's price crash to $24,000. However, he said that this...
Industrial Cannabis Production to be Promoted in Santa Fe
Last week, a bill was introduced in the Argentinian Chamber of Deputies that promotes the production of hemp and non-psychoactive...
Beekeeping Sector in Burkina: Two Hundred Beekeepers Receive Subsidized Production Kits
A total of 200 beekeepers from the 13 regions will benefit from these beekeeping kits subsidized by the European Union....
IgG Antibodies to SARS-CoV-2 Acquired after Natural Infection are Maintained Beyond 12 Months
A seropersistence study shows that IgG antibodies generated after natural infection are maintained beyond 12 months. This study reveals that...
Business7 days ago
Junior Miner Rockridge Resources Untouched By China Copper Price War as Green Energy Transition Heats Up
Biotech7 days ago
Roche is Awarded the Distribution of Reagents in Soria for Two Million Euros
Crowdfunding7 days ago
AZ Eltif ALICrowd Co Invests One Million in the Startup Fessura through Mamacrowd
Africa7 days ago
Agricultural Aggregation: New Procedures for Granting Subsidies in Morocco